Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
On Thursday, French drugmaker Servier lost its court battle against a European Union fine for deals with rivals to delay sales of generic copies of its top-selling blood pressure medicine perindopril. The EU court also upheld a ₹125.62 crore fine on Unichem for a patent dispute settlement. Additionally, the court confirmed sanctions on companies that signed 'pay-for-delay' agreements for their generics. On June 28, Lupin's final appeal against a €40 million fine related to the perindopril case, dated 2014, was dismissed, and the company is required to pay the fine and interest.
News Alert | Lupin: EU Court dismisses appeal against €40 mn fine dated 2014 @LupinGlobal https://t.co/1YkrabYxze
#JustIn | EU Court dismisses Lupin’s final appeal against EU commission order for fine of €40 m #Lupin to pay €40 m fine & interest thereon to EU commission for Perindopril Case https://t.co/3RIok4LrYu
Not only the Court confirmed the sanction on the originator of the reference drug, but they also confirmed the sanction on the companies who agreed with that originator for signing "pay-for-delay" agreements for their generics. Interesting case. https://t.co/vvXriX0A0Z
